bioAffinity Technologies

[bioAffinity Technologies @bioAffinity]

@proactive_x Thank you for the meaningful conversation with our CEO Maria Zannes!

[bioAffinity Technologies @bioAffinity]

From physician adoption to expanding access for U.S. veterans, bioAffinity Technologies CEO Maria Zannes discusses the next steps for #CyPathLung and the company’s broader lung diagnostics work in a new @proactive_x interview with @stephengunnion.

https://t.co/kXH21oVxyb $BIAF

[Proactive @proactive_x]

bioAffinity Technologies CEO: Record CyPath Lung testing fuels growth ambitions @bioAffinity https://t.co/QEZ80ZM14I #CyPath #Lungcancer #Cancer #Lung #Cytometry #AI #COPD #Asthma #BIAF

[bioAffinity Technologies @bioAffinity]

@proactive_x Thank you for sharing our news!

[bioAffinity Technologies @bioAffinity]

Today, bioAffinity Technologies ($BIAF) reported CyPath® Lung reached record monthly testing volume in October, with 235 tests performed, up 29% year over year.

Read more: https://t.co/aOlfFWlR61

[bioAffinity Technologies @bioAffinity]

This Veterans Day, we honor the men and women who served and the experiences that shape their lives beyond military duty.

Supporting our veterans means caring deeply for their long-term health and well-being. Today and every day, we thank you for your sacrifice.

[bioAffinity Technologies @bioAffinity]

#CyPathLung combines flow cytometry, AI-driven analysis and a proprietary fluorescent porphyrin to examine cell populations in patient sputum. This approach provides a closer look at the lung microenvironment to help assess lung cancer risk.

https://t.co/Okp2Bq5YTn $BIAF

[bioAffinity Technologies @bioAffinity]

$BIAF reported third quarter 2026 results and continued progress across its commercial and research programs. CyPath® Lung test unit sales doubled year to date, while testing revenue increased 79% for the first nine months of 2026.

Read more: https://t.co/uoGzIE8lYx

[bioAffinity Technologies @bioAffinity]

One pulmonary nodule can lead to very different decisions depending on the patient. #CyPathLung adds another data point to help physicians assess malignancy risk and determine what may make sense as the next step.

https://t.co/Okp2Bq5YTn $BIAF

[bioAffinity Technologies @bioAffinity]

bioAffinity Technologies is joining tonight’s @LC_Initiative_ Battle of the Blues in Raleigh, where clinicians will discuss updates in thoracic oncology, including how #CyPathLung is detecting lung cancer at earlier stage when treatment can result in cure. $BIAF

[bioAffinity Technologies @bioAffinity]

🪡The study showed 88% specificity and 82% sensitivity overall, with 87% specificity and 92% sensitivity in participants with nodules under 20 mm.

Learn more: https://t.co/P5ntQpLV86 $BIAF (3/3)

[bioAffinity Technologies @bioAffinity]

🧵Testing a lung cancer diagnostic against healthy people is one thing.

Testing it against people at high risk for the disease is another. $BIAF (1/3)

[bioAffinity Technologies @bioAffinity]

🪡That is how the CyPath® Lung validation trial was designed, comparing high-risk participants with and without lung cancer.

The goal was to evaluate the test in the population where it is intended to be used. $BIAF (2/3)

[bioAffinity Technologies @bioAffinity]

@MPOmagazine @AvMEDICALLLC @DeptVetAffairs Thank you for highlighting our partnership with AvMEDICAL!

[bioAffinity Technologies @bioAffinity]

Expanding access to federal healthcare is the focus of bioAffinity Technologies’ distribution agreement with @AvMEDICALLLC.

@MPOmagazine covers the partnership and its plans for #CyPathLung in VA medical centers nationwide.

Read the article: https://t.co/SCPZFqnv3q $BIAF

[bioAffinity Technologies @bioAffinity]

Behind every care journey is a community of people. 🤍

This National #LungCancerAwarenessMonth, we recognize those living with lung cancer, their loved ones and caregivers, and the many healthcare professionals who help guide and support them.

[bioAffinity Technologies @bioAffinity]

An indeterminate pulmonary nodule can leave patients wondering what happens next. #CyPathLung provides additional information to help clinicians assess malignancy risk and determine whether moving forward with an invasive procedure makes sense.

https://t.co/Okp2Bq5YTn $BIAF

[bioAffinity Technologies @bioAffinity]

During #LungCancerAwarenessMonth, $BIAF is highlighting the importance of early lung cancer detection, which can lead to curative therapy. The company will share information about CyPath® Lung at Battle of the Blues on Nov. 5.

Read more: https://t.co/l2RNLyLO6J

[bioAffinity Technologies @bioAffinity]

.@LC_Initiative_'s #BattleOfTheBlues brings thoracic oncology updates to Raleigh on Nov. 5. bioAffinity Technologies will be there to share how physicians are detecting lung cancer at its earliest stage leading to better outcomes using noninvasive #CyPathLung. $BIAF